DNA was extracted from tumor tissues using
GeneRead DNA FFPE Kit (Qiagen 180134, Hilden, Germany) and from peripheral blood lymphocyte with
TGuide S32 Magnetic Blood Genomic DNA Kit (TIANGEN DP601-T5C China) according to the manufacturer’s recommended protocol. Cell free DNA (cfDNA) was extracted using
MagMAX Cell-Free DNA Isolation kit (ThermoFisher, A29319 USA). DNA samples were quantified with the
Qubit dsDNA HS Assay kit (Life Technologies, Q32854 USA) following the manufacturer’s instructions. Genomic DNA was sheared into 150-200 base pairs (bp) fragments through Covaris
LE220 using the recommended settings for NGS library preparation.
KAPA Hyper Prep Kit (KAPA Biosystems, Massachusetts, KK8504 USA) was used for fragmented DNAs construction according to the manufacturer’s instruction. All fragmented gDNA or cfDNA (10 to 50 ng) was end-repaired, sequencing adaptor-ligated, and PCR amplified before purification with
0.8X Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, A63882 USA). The concentration and quality of the library was determined using the Qubit 3.0 system and
Bioanalyzer 2100 (Agilent,
Agilent HS DNA Kit, 5067-4626).
Jiang T., Chen J., Xu X., Cheng Y., Chen G., Pan Y., Fang Y., Wang Q., Huang Y., Yao W., Wang R., Li X., Zhang W., Zhang Y., Hu S., Guo R., Shi J., Wang Z., Cao P., Wang D., Fang J., Luo H., Geng Y., Xing C., Lv D., Zhang Y., Yu J., Cang S., Zhang Y., Zhang J., Yang Z., Shi W., Zou J., Zhou C, & Ren S. (2022). On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Molecular Cancer, 21, 4.